The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

Background. Recommended human immunodeficiency virus (HIV) treatment regimens in the United States contain 3 antiretroviral agents, costing >$30 000/person/year. Pilot studies are evaluating the efficacy of dual therapy with dolutegravir (DTG) and lamivudine (3TC). We examined the potential cost-...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Infect Dis
Autores principales: Girouard, Michael P., Sax, Paul E., Parker, Robert A., Taiwo, Babafemi, Freedberg, Kenneth A., Gulick, Roy M., Weinstein, Milton C., Paltiel, A. David, Walensky, Rochelle P.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2016
Materias:
HIV/AIDS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4772845/
https://ncbi.nlm.nih.gov/pubmed/26658053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ981
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares